Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
Brook
Matthew O
MO
Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, United Kingdom.
Jones
Nick D
ND
Wood
Kathryn J
KJ
D000818:Animals; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte / Q000627:therapeutic use*; D019013:CD40 Antigens / Q000276:immunology*; D023201:CD40 Ligand / Q000276:immunology*; D006084:Graft Rejection / Q000517:prevention & control*; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D060945:Inducible T-Cell Co-Stimulator Ligand; D060889:Inducible T-Cell Co-Stimulator Protein; D008024:Ligands; D011506:Proteins / Q000627:therapeutic use*; D051381:Rats; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D023001:Transplantation Tolerance; D014184:Transplantation, Homologous
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D019013:CD40 Antigens; C556692:ICOS protein, human; C498514:ICOSLG protein, human; D060945:Inducible T-Cell Co-Stimulator Ligand; D060889:Inducible T-Cell Co-Stimulator Protein; D008024:Ligands; D011506:Proteins; D023201:CD40 Ligand